A Spin-Out From Gustave Roussy Tests Four Sanofi Drugs in Silicon

The Paris-based spin-out from Europe's leading cancer center is betting its AIxBio engine can de-risk oncology drug development.

About Orakl Oncology

Published

In a lab outside Paris, tiny clusters of human cells, grown from real patient tumors, are being dosed with experimental cancer drugs. The goal is not just to see if a compound works, but to build a living, breathing dataset that can tell a pharmaceutical company, with high confidence, whether its multi-million dollar clinical trial will succeed or fail. This is the core of Orakl Oncology, a startup that argues the future of oncology R&D lies not in artificial intelligence or biology alone, but in a deeply integrated marriage of the two [Orakl Oncology].

Founded in 2023 as a spin-out from the Gustave Roussy Institute, one of Europe's premier cancer centers, Orakl has now secured a $34 million Series A to scale its vision. The round was co-led by Norrsken VC and Singular, with participation from InfraVia, Serena, and the Patient Autonome Fund, among others, bringing total disclosed funding to roughly $50 million [PERPLEXITY SONAR PRO BRIEF]. The company reports its Series A was oversubscribed, a signal that investors are buying into its hybrid approach at a time when pure-play AI drug discovery platforms face increasing scrutiny over biological translatability [PERPLEXITY SONAR PRO BRIEF].

The AIxBio Wedge

Orakl's differentiation rests on what it calls an "AIxBio" engine, a platform designed to unify wet-lab biology and computational modeling into a single predictive system. The process begins with patient-derived tumor organoids,three-dimensional mini-tumors grown in a dish that retain key characteristics of the original cancer. Orakl tests drug candidates against these living models at scale, generating a proprietary stream of biological response data. This experimental data is then enriched with each patient's longitudinal clinical history, genomic information, and transcriptomic profiles before being fed into machine learning models [Orakl Oncology].

The output is a suite of predictive tools for pharmaceutical partners. The planned product O-Predict is designed to forecast how individual patients will respond to a specific drug candidate. Its counterpart, O-Validate, works in the opposite direction, helping to select or validate the most responsive patient populations for a given therapeutic hypothesis [PERPLEXITY SONAR PRO BRIEF]. The company claims its models have demonstrated 90% accuracy in prospectively predicting individual patient responses across more than 30 clinical trials, and that it closely anticipated recent pancreatic cancer trial results from Revolution Medicines [Orakl Oncology, Artiverse]. While such claims are common in early-stage biotech and require independent peer review for validation, they form the core of Orakl's commercial pitch to de-risk development.

From Academic Roots to Pharma Pipeline

The founding team embodies the company's bridge between academia and industry. CEO Fanny Jaulin, PhD, is a research director at Gustave Roussy with a published track record in cancer cell biology; her work has been cited thousands of times [Fanny Jaulin - Google Scholar, 2026]. She is joined by co-founders Gustave Ronteix, PhD, as CTO, and Diane-Laure Pagès, PhD, as COO, bringing together expertise in computational biology and operational scaling [PERPLEXITY SONAR PRO BRIEF]. The spin-out was built on roughly a decade of underlying research from the institute, providing a foundational scientific credibility that many de novo AI startups lack [PERPLEXITY SONAR PRO BRIEF].

Traction, at least in early commercial discussions, appears strong. The company reports a commercial pipeline involving 18 of the world's 20 largest pharmaceutical companies, though it has named only one partner publicly [PERPLEXITY SONAR PRO BRIEF]. That partner is Sanofi; in July 2026, Orakl obtained rights to test four of the pharma giant's cancer drugs, though the financial terms and specific indications were not disclosed [PERPLEXITY SONAR PRO BRIEF]. Orakl also states it is in contract discussions with more than 15 cancer centers to access patient samples and clinical data, and plans to support partners across more than 10 active drug-development programs [PERPLEXITY SONAR PRO BRIEF].

The company's funding history shows a rapid ascent from its academic origins.

2023 Pre-seed | 3.2 | M USD
2024 Seed | 11 | M USD
2026 Series A | 34 | M USD

The Risks of a Two-Handed Game

Orakl's ambitious integration of physical biology and AI is also its most significant operational complexity. Building and maintaining a high-throughput organoid lab is capital- and expertise-intensive, a very different cost structure from a software-only AI platform. The company plans to use its Series A capital to produce five times more laboratory data and expand its platform into lung and gastric cancers, indicating that scaling the biological data engine is a primary financial sink [PERPLEXITY SONAR PRO BRIEF].

The competitive landscape, while not named in sources, is implicitly crowded. Orakl must contend with:

  • Pure-play AI discovery platforms that offer faster, cheaper computational screening but may lack biological grounding.
  • Large CROs and diagnostic labs with massive scale in patient-derived models but less sophisticated AI integration.
  • In-house efforts at major pharmaceutical companies, which are increasingly building similar capabilities.

Orakl's answer is that its native combination is unique. The deep clinical anchoring from its Gustave Roussy lineage and the closed-loop between lab results and model training are meant to create a moat that neither pure software nor pure service providers can easily replicate [Norrsken VC]. The true test will be whether this moat translates into contracted revenue that justifies the high burn rate of running both a wet lab and an AI team.

The Next Twelve Months

With the new capital, Orakl's immediate roadmap is clear: expand its biological dataset, grow its team, and convert its reported pipeline of pharma discussions into multi-year collaborations. The company is hiring across scientific, data, and commercial roles, including for a Senior AI Engineer and an Alliance Manager for oncology partnerships [Benoît Linsey Fazi - Orakl Oncology, Gizem Altay - Orakl Oncology]. A planned geographic expansion into the United States and United Kingdom will be crucial for engaging the largest oncology R&D budgets and patient populations [PERPLEXITY SONAR PRO BRIEF].

For patients facing colorectal or pancreatic cancers,Orakl's initial focus,the standard of care today often involves sequential lines of chemotherapy with diminishing returns and significant toxicity [Orakl Oncology raises €3 million to develop its techbio platform for precision oncology - BioSpace]. The process of matching a patient to a potentially effective therapy, especially in later lines of treatment, remains more art than science. Clinical trials, meanwhile, continue to suffer from a high failure rate; only an estimated 5% of oncology drug candidates that enter trials ultimately reach patients [Mathieu Raul - Orakl Oncology | LinkedIn, 2026]. Orakl's entire premise is that better, biologically-grounded prediction can tilt those odds, steering resources toward therapies more likely to help and away from those almost certain to fail. The next year will show if pharmaceutical partners are willing to pay upfront for that promise, betting that virtual patients can make real-world trials less of a gamble.

Sources

  1. [Orakl Oncology] Company Website | https://www.orakl-oncology.com/
  2. [PERPLEXITY SONAR PRO BRIEF] Orakl Oncology Company Brief
  3. [Artiverse] Orakl’s $34 Million Bet on Virtual Cancer Patients
  4. [Fanny Jaulin - Google Scholar, 2026] Fanny Jaulin Academic Profile
  5. [Norrsken VC] Bringing better treatments to patients faster: Why we’ve invested in Orakl | https://www.norrsken.vc/news/orakl-oncology
  6. [Benoît Linsey Fazi - Orakl Oncology, 2026] LinkedIn Post on Hiring
  7. [Gizem Altay - Orakl Oncology, 2026] LinkedIn Post on Hiring
  8. [Orakl Oncology raises €3 million to develop its techbio platform for precision oncology - BioSpace] Funding Announcement
  9. [Mathieu Raul - Orakl Oncology | LinkedIn, 2026] LinkedIn Post on Drug Development Statistics

Read on Startuply.vc